ROSELAND, N.J., June 10, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced the appointment of its first Chief Medical Officer, Jo Ellen Schweinle, MD, distinguished former Senior Medical Officer at the U.S. Department of Health and Human Services; Senior Clinical Director at Bayer Corporation, GlaxoSmithKline, McNeil Pharmaceuticals, Chiron/Novartis, and VP Medical Affairs at Axcan Pharma.
“We are privileged to have Dr. Schweinle join our Executive Leadership Team as an accomplished physician, scientist, and clinical investigator. She is a renowned medical voice and noted authority in the use of self-donated stem cells and burn therapies, cornerstones of our CellMist™ and SkinGun™ technologies for the isolation and spray of a patient’s own cells onto burns and wounds,” said Mr. Alan L. Rubino, RenovaCare CEO and President.
Dr. Schweinle, an award-winning physician-researcher, has led and managed numerous worldwide clinical studies. In her most recent role at U.S. Health and Human Services, Dr. Schweinle provided her clinical acumen towards the clinical development of a wide array of burn wound product candidates including therapeutics, debridement agents, and medical imaging devices.
“Dr. Schweinle, with whom I worked with for many years at BARDA, brings us over 30 years of medical, regulatory, and clinical trial expertise from global healthcare organizations and some of the world’s leading government and commercial teams. Her addition strengthens our clinical and regulatory programs for investigation into new and promising cell therapies using skin and other tissue sources and our patented CellMist System™ and SkinGun™ device,” explained, Dr. Robin A. Robinson, Chief Scientific Officer for RenovaCare.
“I am honored to be joining RenovaCare, an innovator at the forefront of cell isolation and regenerative spray technologies that has set a new standard for next-generation cell spray therapies,” said Dr. Schweinle. “RenovaCare innovations for the treatment of burns and wounds, and for tissue and organ regeneration, have the potential to help improve the quality of life for millions around the world. I look forward to my new role at RenovaCare and opening new windows of opportunity for advancing patient care.”
In addition to her decades of commercial experience, Dr. Schweinle is the recipient of numerous honors and grants. She began her career teaching and researching infectious diseases at the University of Texas, National Institutes of Health and at Yale University School of Medicine. She has been published in major scientific journals including Clinical Infectious Diseases, Health Security, Vaccine, and Epidemiol.
Over 70 patients with various types of second-degree burns have been treated on an experimental basis utilizing the technology underlying the Company’s SkinGun™, which RenovaCare has developed as a potential alternative to skin grafting and other treatment options. Sprayed with a gentle mist of their own skin cells, many of these patients left the hospital within days, avoiding generally painful skin graft surgeries and potentially prolonged hospitalization.
About RenovaCare
RenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. The company’s flagship technology, the CellMist™ System, uses its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds.
RenovaCare is developing its CellMist™ System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.
RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Company’s planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.
For additional information, please call Amit Singh at: 888-398-0202 or visit: https://renovacareinc.com.
To receive future press releases via email, please visit:
https://renovacareinc.com/investors/register/.
Follow us on LinkedIn: https://www.linkedin.com/company/renovacare-inc-/.
Follow us on Twitter: https://twitter.com/RenovaCareInc.
Follow us on Facebook: https://www.facebook.com/renovacarercar.
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first. We encourage investors, the media, and others interested in the company to review the information we post on the company’s website and the social media channels listed below:
- Twitter
* This list may be updated from time to time.
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the “Company”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Company’s product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Company’s technologies, technical problems with the Company’s research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company’s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company’s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.